Barbara Grüner
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Year:
2026
Supplementary Table S1. Discovery cohort of vital cells; Supplementary Table S2. Validation cohort/FFPE tissue samples; Supplementary Table S3. Differentially regulated genes; Supplementary Table S4. Selected gene variants compared between the paired treatment-naive vs. relapse cell samples.
Year:
2025
Extended Data relating to Main Figure 4/Targeting of AKT-driven subclonal progression of ALDH1A1+ cells. A, Collected source data for main Figs. 4B,C,F-H. Left, diagrams: in vitro cell confluence dynamics of paired treatment naive vs. TMZ-related experimental (TMZ→eR; BN46) or clinical (RT/TMZ; BN118, BN123, BN132) relapse patient cells. Monitoring of cell confluence by software-based cell recognition. Assay specified in Fig. 4A. Right, graphs: Readout results from the indicated cases in line, representing source data for Figs. 4B (Cell Confluence), 4C (Cell Viability), and 4H (Apoptosis). Respective assays specified in the main Figure Legends. Data as mean ± SD. p values calculated by pairwise Wilcoxon rank-sum test followed by multiple testing correction using Benjamini-Hochberg method. B, IF of ALDH1A1 and Ki67 in the BN46-donor cell tumor PDX model. Shown is an example from a TMZ+MK2206-treated mouse (OS = 148 days; low levels of cellular co-expression). Scale bar: 20 µm. C, Comparison of overall survival under the investigated treatment conditions (refer to Fig. 4J). Hazard ratio 95% confidence interval estimates and significance levels derived from Cox regression are shown.
Year:
2025
Validation cohort, patient flow diagram. Patient enrollment and final inclusion of FFPE tissue samples in this study is shown. n = 3 patients were excluded from enrollment for reasons listed. The validation cohort comprised paired tissue samples from a total of n = 38 patients. Detailed characteristics in Supplementary Table S4. Note, the separate discovery cohort of paired vital cells is detailed in Supplementary Table S1. The GLASS cohort was used as an additional, external reference comprising data on n=37 patients extracted from (10).
Year:
2025
Extended Data relating to Main Figure 2/Assessment of ALDH1A1+ cells from primary, treatment-naive glioblastoma. A, Bar plot shows ALDH-bright (ALDHbr) vital cells from two additional paired cases of naive vs. experimental (TMZ→eR) and clinical (cR) relapse. Data as mean ± SD. p values by one-way analysis of variance (ANOVA) with Tukey´s post-hoc test. B, Dotplot shows ALDH1A1 mean fluorescence intensity (MFI) in paired BN46 treatment-naive vs. experimental relapse conditions (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)). Data are normalized to isotype control, mean ± SD. p values calculated by Kruskal-Wallis test with Dunn's post-hoc test. C, Relative ALDH1A1 expression in -knockdown (shALDH1A1) and -overexpression (Ovx) BN46 cells used for indicated experiment. Data shown as mean ± SD, normalized to their respective controls (ALDH1A1 Ovx to GFP Ctrl | shALDH1A1 to shNT Ctrl). D, Left: Brightfield image of BN46 cells in 96-well plates during monitoring by software-based cell recognition in the limiting dilution assay (NyOne®). An exemplary single cell/well is shown at one day post seeding; representative monoclonal colonies of ALDH1A1-knockdown (sh) and -overexpressing (Ovx) cells at day 16 after seeding. Right: Doubling time estimated at day 16 after seeding (see Methods). Data as mean ± SD, p values calculated by Kruskal-Wallis test with Dunn's post-hoc test. E, Left: Cartoon describes the neurosphere experiments shown in Fig. 2H. Right: Phase contrast microscopic appearance of plated 2° neurosphere and respective immunofluorescence visualization of antibody labeling on neurosphere-derived cells. Neuronal phenotype, β3-tubulin (β3-tub); glial phenotypes, glial fibrillary acidic protein (GFAP). Nuclei exposed with DAPI. Scale bars: left: 100 µM, right: 50 µM. F, Table showing quantification data of 1° and 2° neurosphere generations from (E) in the respective treatment-naive BN46 cells. G, All plated 2° neurospheres from assay (E,F) generated neuronal and glial cell phenotypes.
Year:
2025
Extended Data relating to Main Figure 3/AKT-driven progression of ALDH1A1+ cells in glioblastoma. A, Flow cytometry histograms showing ALDH1A1 expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3A. Isotype controls in gray. B, Flow cytometry histograms of ALDH1A1 derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data quantification in Supplementary Fig. S2B. C, Cartoon illustrating course of neurosphere experiments, quantified in main Fig. 3B and in Supplementary Fig. S3D, applying treatment-naive and paired experimental and clinical relapse patient cells. Right: Exemplary qRT-PCR data presenting knockdown efficacy of the siRNA approach in respective cells, normalized to siNT control. Mean of duplicates ± SD. D, Source data for Fig. 3B, and for Supplementary Fig. S3E. Dotplots show percent neurosphere-forming cells estimated from neurospheres at 12 days after seeding. Paired patient cell analysis, evaluating 1° and 2° neurospheres of indicated knockdown (siALDH1A1) and respective control (siNT) cell samples. Data shown as mean ± SD. E, Neurosphere assay, similar to main Fig. 3B on paired treatment-naive vs. experimental relapse (TMZ→eR) BN46 cells. Source data in Supplementary Fig. S3D. Data as mean ± SD. F, Protein patterns, similar to Fig. 3D. on paired cells from 2 additional discovery cohort samples. G, Flow cytometry histograms depicting pAKT(Ser473) expression in the paired treatment-naive vs. clinical relapse patient samples quantified in main Fig. 3E. Isotype controls in gray. H, Flow cytometry histograms of pAKT(Ser473) and, right, quantification of data derived from treatment-naive and paired experimental relapse (TMZ→eR) BN46 cells. Data represent mean fluorescence intensities (MFI), ± SD, normalized to isotype control (gray). I, Representative source data for Fig. 3F. Flow cytometry profiles of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. clinical relapse cell samples. J, Flow cytometry profiles of of ALDH1A1/pAKT(Ser473)-labeled, paired treatment-naive vs. experimental relapse conditions of BN46 cells (in vitro exposure to TMZ (TMZ→eR) or irradiation (RT→eR)).
Year:
2025
Proteolysis-targeting chimeras (PROTACs) co-op the ubiquitin system for targeted protein degradation, creating opportunities to interrogate cellular functions of proteins through “chemical knockdown”. However, matched pairs of protein degraders and inhibitors, that possess high specificity and chemical complementarity, for individual components of the ubiquitin system have remained scarce. This includes reagents to modulate activity and abundance of deubiquitinases (DUBs), which critically regulate ubiquitin-mediated signaling. Here, using an integrated chemical biology approach, we explored the cellular function of the DUB USP7 as a case study comparing inhibition and degradation of this DUB in melanoma and pancreatic cancer cells. Through the synthesis of a degrader library, we identified potent USP7 PROTACs for each cancer type, established BRET-based ternary complex formation and quantified degradation efficiency. USP7 degraders and their cognate inhibitor were subsequently employed to characterize treatment-induced phenotypic alterations. Proteomic and cellular analyses revealed that highly specific degradation of USP7 modulated both shared and distinct protein sets across cancer cell types, without impacting cell growth. Notably, cellular responses to USP7 degradation differed markedly from those to USP7 inhibition. Moreover, our data uncovered broad proteomic and metabolic changes induced by prolonged USP7 inhibitor treatment. Collectively, our work provides a chemical toolbox of comprehensively characterized reagents to distinguish on-target phenotypes which will aid the understanding of the role of USP7 in malignant diseases. More broadly, our data emphasize the importance of increased specificity via PROTAC-mediated degradation and the potential of this modality to distinguish catalytic from non-catalytic as well as cell-line specific functions of DUBs.
Year:
2025
Lung cancer, the leading cause of cancer mortality, exhibits diverse histologic subtypes and genetic complexities. Numerous preclinical mouse models have been developed to study lung cancer, but data from these models are disparate, siloed, and difficult to compare in a centralized fashion. In this study, we established the Lung Cancer Autochthonous Model Gene Expression Database (LCAMGDB), an extensive repository of 1,354 samples from 77 transcriptomic datasets covering 974 samples from genetically engineered mouse models (GEMM), 368 samples from carcinogen-induced models, and 12 samples from a spontaneous model. Meticulous curation and collaboration with data depositors produced a robust and comprehensive database, enhancing the fidelity of the genetic landscape it depicts. The LCAMGDB aligned 859 tumors from GEMMs with human lung cancer mutations, enabling comparative analysis and revealing a pressing need to broaden the diversity of genetic aberrations modeled in the GEMMs. To accompany this resource, a web application was developed that offers researchers intuitive tools for in-depth gene expression analysis. With standardized reprocessing of gene expression data, the LCAMGDB serves as a powerful platform for cross-study comparison and lays the groundwork for future research, aiming to bridge the gap between mouse models and human lung cancer for improved translational relevance. Significance: The Lung Cancer Autochthonous Model Gene Expression Database (LCAMGDB) provides a comprehensive and accessible resource for the research community to investigate lung cancer biology in mouse models.
Year:
2025
Purpose: Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy. Experimental Design: To identify candidate markers and to experimentally access dynamics of subclonal progression in glioblastoma, we established a discovery cohort of paired vital cell samples obtained before and after primary therapy. We further used two independent validation cohorts of paired clinical tissues to test our findings. Follow-up preclinical treatment strategies were evaluated in patient-derived xenografts. Results: We describe, in clinical samples, an archetype of rare ALDH1A1+ tumor cells that enrich and acquire AKT-mediated drug resistance in response to standard-of-care temozolomide (TMZ). Importantly, we observe that drug resistance of ALDH1A1+ cells is not intrinsic, but rather an adaptive mechanism emerging exclusively after TMZ treatment. In patient cells and xenograft models of disease, we recapitulate the enrichment of ALDH1A1+ cells under the influence of TMZ. We demonstrate that their subclonal progression is AKT-driven and can be interfered with by well-timed sequential rather than simultaneous antitumor combination strategy. Conclusions: Drug-resistant ALDH1A1+/pAKT+ subclones accumulate in patient tissues upon adaptation to TMZ therapy. These subclones may therefore represent a dynamic target in glioblastoma. Our study proposes the combination of TMZ and AKT inhibitors in a sequential treatment schedule as a rationale for future clinical investigation.
Year:
2025
Collaborators (42)
Stefan Knapp
Goethe University Frankfurt
Nina Schulze
Universität Duisburg-Essen
Kekoa Taparra
Assistant Professor
University of California, Los Angeles
John Minna
Professor and Direcdtor
University of Texas Southwestern Medical Center
Vassilis Aidinis
Biomedical Sciences Research Center Alexander Fleming
Phuoc T. Tran
University of Maryland
Kathy Keyvani
Head/Professor
University of Duisburg-Essen Faculty of Medizin
Verena Jendrossek
Head of Department
-
Martin Glas
University Hospital Essen
Pawel Mazur
Associate Professor
The University of Texas MD Anderson Cancer Center
Oliver Brüstle
University of Bonn
Roger A. Moorehead
University of Guelph
Ralph J. DeBerardinis
University of Texas Southwestern Medical Center
Charles Rudin
Memorial Sloan Kettering Cancer Center
J. Edward van Veen
Assistant Adjunct Professor
University of California, Los Angeles
Daniel Hoffmann
Professor
Universität Duisburg-Essen
George Acquaah-Mensah
Professor of Pharmaceutical Sciences
Massachusetts College of Pharmacy and Health Sciences
Yonathan Lissanu
The University of Texas MD Anderson Cancer Center
Trudy G. Oliver
Duke University
YING GAO
University of Texas Southwestern Medical Center
Johann Matschke
-
David MacPherson
Professor
Fred Hutch Cancer Center
Giorgio Ramadori
Scientific Collaborator
University of Geneva
Rosanna Martinelli
Professor of Molecular Biology
Università degli Studi di Napoli Federico II
Malte Gersch
Professor
Universität Duisburg-Essen
Min Gyu Lee
Professor
The University of Texas MD Anderson Cancer Center
Annette Paschen
University Hospital Essen
Farnusch Kaschani
Head of Analytics Core Facility Essen
Universität Duisburg-Essen
Christel Herold-Mende
University Hospital Heidelberg
Michael Weller
University Hospital of Zurich
Björn Scheffler
University Hospital Essen
Jens Siveke
Director
Deutsches Krebsforschungszentrum
Alexander Roesch
Professor of Dermatological Oncology, Chief Physician, Head of Dermato-Oncology Research Unit
University Hospital Essen
Holger Fröhlich
Full Professor for Biomedical Data Science
University Hospital Bonn
Shyam Biswal
Professor
Johns Hopkins University
Arun Pandiri
Staff Scientist
National Institute of Environmental Health Sciences
CHARLES POWELL
Division Chief/Professor of Medicine
Icahn School of Medicine at Mount Sinai
Jennifer Beane-Ebel
Assistant Professor
Boston University School of Medicine
Andreas Till
head of data platform
Rheinische Friedrich-Wilhelms-Universität Bonn
Markus Kaiser
Universität Duisburg-Essen
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.